Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | RAD52 | P43351 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17976399 | 0.98 | ALDH1A1 (0.68) | HPGDALDH1A1KDM4EHTTMEN1 | |
| SCHEMBL21416724 | 0.84 | MEN1 (0.60) | HPGDALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL13118344 | 0.81 | HPGD (1.00) | HPGDALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL791289 | 0.80 | MEN1 (0.71) | HPGDALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL31030743 | 0.80 | ALDH1A1 (0.77) | HPGDALDH1A1KDM4EHTTMEN1 | |
| SCHEMBL5501404 | 0.80 | NPC1 (0.70) | HPGDALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL2548511 | 0.79 | ALDH1A1 (0.75) | HPGDALDH1A1KDM4EHTTMEN1 | |
| SCHEMBL14568633 | 0.79 | NPC1 (0.72) | HPGDALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL1644836 | 0.78 | ALDH1A1 (0.97) | ALDH1A1HTTMEN1KMT2AGAA | |
| SCHEMBL3455874 | 0.78 | ALDH1A1 (1.00) | HPGDALDH1A1KDM4EHTTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120058085-A1 | Deuterium Modified Benzimidazoles | CONCERT PHARMACEUTICALS, INC. | 2012-03-08 | — | — | US | disclosed |
| US-20120058085-A1 | Deuterium Modified Benzimidazoles | CONCERT PHARMACEUTICALS, INC. | 2012-03-08 | — | — | US | disclosed |
| WO-2010132810-A1 | DEUTERIUM MODIFIED BENZIMIDAZOLES | CONCERT PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058085-A1 | Deuterium Modified Benzimidazoles | POLRMT, EIF2AK2, DUT | HPGD 953/4885ALDH1A1 1179/4885KDM4E 537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.